AI Drugmakers Move Research Capabilities Deeper In-House
An industry assessment says AI drug-development capabilities remain concentrated in early discovery, with commercial value often stopping before PCC selection. [[fact:fact-64qwis0ki]] AI drug companies are increasingly exploring licensing deals while retaining selected projects in their own clinical pipelines. [[fact:fact-8a620fd13]] An interviewed industry view says some innovative drugmakers are building AI research infrastructure to retain accumulated biological data and create a computational and automated experimental-validation loop. [[fact:fact-lavk2n91z]] Lei Ming said MegaStream upgraded project-based cooperation to an independent joint venture coordinating model development, data use, experimental validation, and candidate-drug advancement. [[fact:fact-x2o5a4vga]] A report says neuroscience targets discovered by Recursion and Genentech entered early small-molecule drug development in August 2026. [[fact:fact-5asvbi7vf]]